featured
Pembrolizumab Plus Concurrent Chemoradiotherapy for Locally Advanced HNSCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
Lancet Oncol 2024 Mar 29;[EPub Ahead of Print], JP Machiels, Y Tao, L Licitra, B Burtness, M Tahara, D Rischin, G Alves, IPF Lima, BGM Hughes, Y Pointreau, S Aksoy, S Laban, R Greil, M Burian, M Hetnał, JP Delord, R Mesía, M Taberna, JN Waldron, C Simon, V Grégoire, KJ Harrington, RF Swaby, Y Zhang, B Gumuscu, B Bidadi, LL SiuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.